# A Psychedelics Biotech Company

## Corporate Presentation

March 2021

**CSE: PHRM | OTCQB: PHRRF**

# Forward Looking Statements

This presentation of Newscope Capital Corporation (dba PharmaTher Inc.) (“PharmaTher”) contains "forward-looking information", which may include, but is not limited to, statements with respect to anticipated business plans or strategies of PharmaTher, the anticipated date of completion of research studies, the timing of any drug trials, the success of its clinical trials, the ability to enter into licenses, acquisitions or collaborations to enhance its drug development platform, the success of any such licenses, acquisitions or collaborations and the ability to use the information relating to, or obtain patents or other intellectual property protection on, data and clinical trials generated directly by PharmaTher or through such licenses, acquisitions or collaborations, and the success or stage of development of discoveries or medicines. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", or "believes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of PharmaTher to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption “Risk Factors” in PharmaTher’s management’s discussion and analysis for the period of August 30, 2020 (“MD&A”), dated October 1, 2020, which is available on PharmaTher’s profile at www.sedar.com. Forward-looking statements contained herein are made as of the date of this presentation and PharmaTher disclaims, other than as required by law, any obligation to update any forward-looking statements whether as a result of new information, results, future events, circumstances, or if management's estimates or opinions should change, or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements.

# We are a *Psychedelics Biotech* company

## OUR FOCUS

Developing next generation psychedelic pharmaceuticals for FDA approval



## OUR PLATFORMS

Novel uses and formulations of ketamine and delivery of psychedelics in a patented transdermal microneedle patch

## OUR MARKETS

Neuropsychiatric, neurological and neuromuscular diseases

# Psychedelics as a prescription leading the way

| COMPASS Navigating Mental Health Pathways | mindmed | PHARMATHER | atai LIFE SCIENCES | Small Pharma |
|---|---|---|---|---|
| Psilocybin | LSD | Ketamine | Multiple psychedelics | DMT |
| Depression | Anxiety | Parkinson's, Depression | Mental Illness | Depression |
| Phase 2b clinical trial | Phase 2 in Q3-2021 | Phase 2 in Q2-2021 | Investors in various psychedelic co's | Phase 1/2 |
| $1.48 Billion valuation | $1.54 Billion valuation | $16 Million valuation | $2 Billion valuation | $325 Million valuation |

**** CAD$ As of March 5, 2021***

# Our strategy puts us on a path to deliver

1. Pursue innovative psychedelics as a prescription for ***FDA approval***
2. Advance clinical studies of ***Ketamine and KETABET***™ in Parkinson's disease, Depression and Lou Gehrig's disease
3. Develop our proprietary ***Microneedle patch*** to deliver psychedelics better
4. Discover new uses of psychedelics with ***panaceAI***™ drug repurposing AI platform
5. Enhance ***Shareholder value*** through partnerships, patents, licensing and sales

# Our patent portfolio is diverse and expanding

**17** Granted Patent and Provisional Patents

**8** Countries filed
U.S., Europe, Japan, China, Israel, Canada, Taiwan, India




- ✓ ***Parkinson's Disease*** – Compositions and Methods for Treating Motor Disorders
- ✓ ***Lou Gehrig's Disease*** – Extend Survival after Muscle Wasting in Amyotrophic Lateral Sclerosis

- ✓ **Microneedle patch –** Method and device for delivering psychedelics and cannabinoids
- ✓ ***Ketamine Combination*** – Method and composition for decreasing the side effects and addictive disorder of ketamine
- ✓ ***panaceAI*™ –** Method of identifying new medical indications for psychedelics with artificial intelligence

# Our relationships are strong

**Ketamine**
Parkinson's disease

**Microneedle delivery**
Ketamine

**Microneedle delivery**
Psilocybin, DMT, LSD, MDMA

**Ketamine**
Amyotrophic Lateral Sclerosis
(Lou Gehrig's Disease)

**Ketamine**
Combination formulation

**Sale and Collaboration**
$10M sale and R&D
Psilocybin TBI, Stroke and Cancer

# We are targeting a $100 billion global market

## Neuropsychiatric

**970**

**Million People**

Global Prevalence

Depression, Anxiety, Substance Abuse, Bipolar, Schizophrenia, PTSD

## Neurological

**$800**

**Billion**

Cost Burden in the U.S.

Parkinson's disease, Epilepsy, Alzheimer, Dementia, Multiple Sclerosis

## Neuromuscular

**90**

**Percent**

Agree to be an unmet need

Amyotrophic lateral sclerosis, Duchenne muscular dystrophy

# We are unlocking the potential of ketamine

## *Drug repurposing is a common drug development strategy*

| Drug | Original Use | New Use | Company | Peak Sales |
|---|---|---|---|---|
| KETAMINE / KETABET™ | Anesthetic | Parkinson's, disease, Depression, ALS | PHARMATHER | TBD > $1 billion |
| VIAGRA | Angina | Erectile Dysfunction | Pfizer | $2.05 billion |
| REVLMID | Anti-Nausea | Multiple Myeloma | Celgene | $9.7 billion |
| TECFIDERA | Psoriasis | Multiple Sclerosis | Biogen/IDEC | $4 billion |
| RITUXAN | Cancers | Rheumatoid Arthritis | Biogen / Roche | $7.1 billion |

# Ketamine has significant potential and limitations

FDA approved in 1970 & WHO Model list of Essential Drugs

Strong anesthetic and pain reliver

Clinical evidence in Depression, PTSD and Suicidal Ideation

Esketamine FDA approved in 2019 & growing ketamine clinics


Cognitive impairment
Hallucinations, Blurred Vision, Memory Loss, Nausea, Dizziness

Abuse liability and Tolerance

Increased Blood Pressure, Liver and Bladder Injury

Administered at clinic or hospital by a healthcare professional
Numerous administration sessions lasting several hours each session

# We focus on clinical trials for FDA approval

| Product | Indication | Preclinical | Phase 1 & 2 | Phase 3 | Patients | Market size |
|---|---|---|---|---|---|---|
| **Ketamine** | Parkinson's Disease | | | | 10 million | +$1 billion |
| **KETABET™** | Depression | | | | 100 million | +$5 billion |
| **Ketamine** | ALS – Lou Gehrig's Disease | | | | < 200 thousand | +$1 billion |
| **Microneedle Patch** *Ketamine, Psilocybin, LSD, MDMA, DMT* | Multiple diseases | | | | | |



**FDA 505(b)(2) Regulatory Pathway**

Potential to reduce cost, time and development risk


Opportunities

Current status | Within 12 months

**Appendix:** Drug repurposing successes

# Potential of ketamine to treat Parkinson's disease

## We have the exclusive license to the IP for the use of ketamine to treat PD

### UA Clinical Trial to Repurpose Ketamine for Parkinson's Patients

Jul 18, 2018

The best-known treatment for Parkinson's disease isn't perfect. Named levodopa, the drug can treat the stiffness and slowness of movement associated with the debilitating disease.

"The problem is levodopa works great for a few years — we call that the 'honeymoon' period — but then you start getting these side effects," says **Scott Sherman, MD, PhD**, a neurologist at the University of Arizona College of Medicine – Tucson.



Forty percent of patients on levodopa eventually will experience dyskinesia — uncontrollable and involuntary movements of the arms, legs, head or entire body. Severity can range from small, fidget-like motions to larger continuous bursts of movement.

Unless patients stop levodopa treatment altogether, these movements do not go away.

Now, UA researchers will repurpose ketamine, a drug currently used to treat pain and depression, to try to reduce and control these involuntary movements brought on by levodopa.

## Ketamine has demonstrated efficacy in preclinical and clinical research

- Evidence of tolerability, safety and long-term reduction of abnormal involuntary movements
- Reduces L-DOPA-induced dyskinesia (LID), improve on time and reduce depression
- Shows potential as a novel long-term treatment modality to reduce LID
- Expansion into pain and depression in PD and other movement disorders

Source: https://pubmed.ncbi.nlm.nih.gov/27293405/

# We are changing how psychedelics are delivered

*Prototype microneedle patch*

**Ketamine**
**Psilocybin**
**MDMA**
**DMT**
**LSD**




## Microneedle Patch

- **Patient freedom** – pain-free, home use, convenient and improves compliance
- **Flexible dosing** – drug combinations, continuous delivery and desired release rates
- **Improve efficacy** – maintains constant plasma levels for over 24 hours
- **Next generation delivery** – improvement over intravenous, oral, injection, pumps, topical, nose

# We are developing a new ketamine therapy

## KETABET™







**Cystadane is an FDA-approved drug**



**Hydrogel-forming microneedle patch to deliver a novel ketamine combo formulation**

## Demonstrated potential

- Effective in depression models
- Synergistic combination enhancing efficacy of ketamine
- Reduces side effects of ketamine
  i.e. dissociation, amnesia, motor dysfunctions
- Reduces suicidal thoughts, addiction and abuse liability

Source: Betaine enhances antidepressant-like, but blocks psychotomimetic effects of ketamine in mice

# We have deep R&D, clinical & financial expertise

## Management

**Fabio Chianelli**
*Chairman & CEO*
- Past Founder, CEO, President of Revive Therapeutics Ltd.

**Owen Van Cauwenberghe, PhD**
*Research and Development*
- Principal Research Scientist and Director at Eli Lilly Canada
- Director at Accucaps Industries Ltd.

**Carmelo Marrelli, CA**
*Chief Financial Officer*
- CFO of multiple TSX and CSE companies

## Scientific & Clinical Advisors

**Dr. Joga Gobburu, PhD**
- Director of Pharmacometrics at FDA

**Dr. Robert A. Hauser MD, MBA**
- Director, USF Parkinson's Disease and Movement Disorders Center

**Dr. Alberto J. Espay MD**
- Chair, U of Cincinnati James J. and Joan A. Gardner Family Center for Parkinson's Disease and Movement Disorders

## Board of Directors

**Fabio Chianelli,** *Chairman & CEO*
- Past Founder, CEO, President of Revive Therapeutics Ltd.

**Dr. Bev Incledon,** *Director*
- EVP and CSO, Ironshore Pharma
- +28 years drug discovery & development

**Christian Scovenna,** *Director*
- +12 years capital markets experience

**Carlo Sansalone,** *Director*
- Past Director of Revive Therapeutics Ltd.

# Upcoming Milestones

## H1-2021

- ✓ **Parkinson's disease** – FDA IND acceptance for Phase 2 clinical study with ketamine
- ✓ **Depression** – FDA IND acceptance of Phase 2 clinical study with KETABET™
- ✓ **Parkinson's disease** – FDA Orphan designation for ketamine
- ✓ **Microneedle Patch** – Research results for ketamine and KETABET™

## H2-2021

- ✓ **Parkinson's disease** – FDA Phase 2 study results with ketamine
- ✓ **Depression** – FDA Phase 2 study results for KETABET™
- ✓ **ALS (Lou Gehrig's)** – FDA IND acceptance for Phase 2 clinical study with ketamine
- ✓ **Microneedle Patch** – Research results for psilocybin, DMT, LSD and MDMA
- ✓ **Microneedle Patch** – Scale-up manufacturing for clinical trials

## Ongoing developments

- Business Development i.e. licenses, partnerships and sales
- Expanding patent portfolio, management, scientific and clinical team

# Financial Snapshot

PHRM LISTED ON CSE™

PHRRF OTCQB

**Newscope Capital Corporation**
(PharmaTher Inc., a wholly-owned subsidiary of Newscope Capital)

| $0.24 | $17M | 69,609,865 I/O Common Shares |
|---|---|---|
| Share Price* | Market Cap* | 3,802,200 Warrants |
| | | 5,000,000 Stock Options |

**Over $7 million in cash and short-term securities***
*(~$3.5 million in cash and $4 million in Revive Therapeutics common stock)*

**** CAD$ As of March 5, 2021***